Yükleniyor... / Loading...
This study examined the efficacy of two treatments, amodiaquine-artesunate (ASAQ) and artemether-lumefantrine (AL), in children with Plasmodium falciparum malaria in Liberia. It enrolled children aged 6-59 months, weighing at least 5 kg, with confirmed P. falciparum infection. The study was in Phase 4 and has been completed.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria 1. Age between 6 to 59 months (5 years) 2. Weight ≥ 5 kg 3. Monoinfection with P. falciparum with a parasite density of 2,000 to 200,000 asexual forms per microliter of blood 4. Axillary temperature ≥37.5˚C or history of fever in the last 24 hours 5. Hemoglobin ≥ 8.0g/dl 6. Easy access to the health facility and ability to return to the health facility over the course of the four weeks of follow-up 7. Informed consent of parent or guardian Exclusion Criteria on Day 0 1. Any danger signs or signs of severe malaria (see Appendix I) 2. Pneumonia or bronchopneumonia 3. Severe malnutrition (Z-score \< 3) 4. History of taking antimalarials (or antibiotics with antimalarial activity such as cotrimoxazole, tetracycline or doxycycline) in the last 14 days 5. Mixed malaria infection 6. History of hypersensitivity or allergy to the medication